Clinical Division of Gynecological Endocrinology and Reproductive Medicine, Department of Obstetrics and Gynecology, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
Department of Obstetrics and Gynecology, Klinik Floridsdorf, Vienna, Austria.
Reprod Biol Endocrinol. 2022 Jul 4;20(1):98. doi: 10.1186/s12958-022-00961-y.
To evaluate in women with functional hypothalamic amenorrhea (FHA), whether there is a difference between patients with and without polycystic ovarian morphology (PCOM) concerning the response to a gonadotropin releasing hormone (GnRH) stimulation test and to pulsatile GnRH treatment.
In a retrospective observational study, 64 women with FHA who underwent a GnRH stimulation test and 32 age-matched controls without PCOM were included. Pulsatile GnRH treatment was provided to 31 FHA patients and three-month follow-up data were available for 19 of these.
Serum levels of gonadotropins and estradiol were lower in FHA women than in controls (p < 0.05). FHA patients revealed PCOM in 27/64 cases (42.2%). FHA patients without PCOM revealed lower anti-Müllerian hormone (AMH) levels than controls (median 2.03 ng/mL, IQR 1.40-2.50, versus 3.08 ng/mL, IQR 2.24-4.10, respectively, p < 0.001). Comparing FHA patients with and without PCOM, the latter revealed lower AMH levels, a lower median LH increase after the GnRH stimulation test (240.0%, IQR 186.4-370.0, versus 604.9%, IQR 360.0-1122.0; p < 0.001) as well as, contrary to patients with PCOM, a significant increase in AMH after three months of successful pulsatile GnRH treatment (median 1.69 ng/mL at baseline versus 2.02 ng/mL after three months of treatment; p = 0.002).
In women with FHA without PCOM, the phenomenon of low AMH levels seems to be based on relative gonadotropin deficiency rather than diminished ovarian reserve. AMH tended to rise after three months of pulsatile GnRH treatment. The differences found between patients with and without PCOM suggest the former the existence of some PCOS-specific systemic and/or intra-ovarian abnormalities.
评估患有功能性下丘脑性闭经(FHA)的女性中,多囊卵巢形态(PCOM)患者与无 PCOM 患者的促性腺激素释放激素(GnRH)刺激试验和脉冲 GnRH 治疗反应是否存在差异。
在一项回顾性观察性研究中,纳入了 64 名接受 GnRH 刺激试验的 FHA 女性和 32 名年龄匹配的无 PCOM 对照组。对 31 名 FHA 患者进行了脉冲 GnRH 治疗,其中 19 名患者有 3 个月的随访数据。
FHA 女性的促性腺激素和雌二醇水平低于对照组(p<0.05)。64 例 FHA 患者中 27 例(42.2%)存在 PCOM。无 PCOM 的 FHA 患者的抗苗勒管激素(AMH)水平低于对照组(中位数 2.03ng/ml,IQR 1.40-2.50,与 3.08ng/ml,IQR 2.24-4.10,分别为 p<0.001)。比较有和无 PCOM 的 FHA 患者,后者的 AMH 水平较低,GnRH 刺激试验后 LH 增加中位数较低(240.0%,IQR 186.4-370.0,与 604.9%,IQR 360.0-1122.0,分别为 p<0.001),并且与有 PCOM 的患者相反,成功的脉冲 GnRH 治疗 3 个月后 AMH 显著增加(基线时中位数 1.69ng/ml,治疗 3 个月后中位数 2.02ng/ml;p=0.002)。
在无 PCOM 的 FHA 女性中,低 AMH 水平的现象似乎基于相对的促性腺激素缺乏,而不是卵巢储备减少。AMH 在接受脉冲 GnRH 治疗 3 个月后趋于升高。有和无 PCOM 的患者之间的差异表明前者存在一些 PCOS 特异性的全身和/或卵巢内异常。